MRK Merck & Co., Inc.
USHealthcareAs of 2026-08-24
Why MRK matters now
Merck & Co., Inc. (MRK) is a US stock in Healthcare. The latest InvestLog snapshot shows $150.74 with -1.19% on the session and $372.30B in market capitalization; recent performance reads 1-month -0.32% and YTD +8.18%.
The latest financial table shown here is Q1 2026, with revenue of $16.29B, net income of $-4.24B, and EPS of $-1.72. Investors can compare that operating picture with valuation signals such as P/E 16.17 and FCF yield 5.0%.
InvestLog's latest related AI research is a Insider Sale note titled "Zachary Jennifer sells $10.7M of MRK". The latest indexable market news headline is "Moderna Sinks 7% as Traders Book Profits on a 392% Year-to-Date Surge; BioNTech Drops 4%, Merck Slips" from 24/7 Wall Street.
Additional event context on this page matters because analyst consensus is Buy with a median target of $135.00; recent insider activity includes BAKER DOUGLAS M JR filing A-Award; recent congressional disclosure data includes Josh Gottheimer Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
16.17
PEG
2.43
P/B
6.14
P/S
4.29
EV/EBITDA
17.31
DCF Value
$204.04
FCF Yield
5.0%
Div Yield
3.0%
Margins & Returns
Gross Margin
75.9%
Operating Margin
27.6%
Net Margin
13.6%
ROE
17.9%
ROA
6.9%
ROIC
13.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $16.29B | $-4.24B | $-1.72 |
| Q4 2025 | $16.32B | $2.96B | $1.19 |
| FY 2025 | $64.93B | $18.25B | $7.28 |
| Q3 2025 | $17.18B | $5.79B | $2.32 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$131.58
Target (Median)
$135.00
Target Range
$100.00 - $150.00
Trading Activity
Insider Trades
Congress Trades
Related AI Research
Zachary Jennifer sells $10.7M of MRKZachary Jennifer 内部减持 默沙东 (MRK) $10.7M
Executive Vice President and General Counsel Zachary Jennifer sold 80,315 shares of Merck & Co. (MRK) common stock on the open market on August 12, 2026, at a price of $133.执行副总裁兼总法律顾问Zachary Jennifer于2026年8月12日以每股133.46美元的价格在公开市场出售80,315股默克(MRK)普通股,交易总价值10,718,495美元,相关Form 4内幕交易申报文件于2026年8月13日提交至美国SEC。该笔交易占默克当前3348亿美元总市值的0.003%。
MRK earnings call: guidance, demand, margins, analyst Q&A默沙东 (MRK) 电话会要点:指引、需求、利润率、分析师问答
Caroline Litchfield: Now turning to our 2026 non-GAAP guidance. We have raised and narrowed our full year revenue guidance range to be between $66.3 billion and $67.3 billion, representing growth of 2% to 4%, including a positive impact from foreign exchange of approximately 1 percentage point using mid-July rates.卡罗琳·利奇菲尔德:现在我们来谈谈2026年非GAAP指引。我们上调并收窄了全年营收指引区间至663亿至673亿美元,对应增长率2%至4%,其中按7月中旬汇率计算的外汇正向影响约为1个百分点。
MRK earnings release — EPS beat +51.9% · revenue beat +1.5%默沙东 (MRK) 财报发布 — EPS 高于预期+51.9% · 营收 高于预期+1.5%
Merck & Co., Inc. reported EPS $-0.13 vs $-0.27 estimate and revenue $16.6B vs $16.4B estimate.默沙东 公布财报:EPS $-0.13 vs $-0.27 预期,营收 $16.6B vs $16.4B 预期。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US
Exchange
—
Beta
0.22
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.